Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors.
about
Antimicrobial Peptides in Human SepsisThe Endothelial Glycocalyx: New Diagnostic and Therapeutic Approaches in SepsisTherapeutical Administration of Peptide Pep19-2.5 and Ibuprofen Reduces Inflammation and Prevents Lethal SepsisBiophysical analysis of the interaction of the serum protein human β2GPI with bacterial lipopolysaccharide.Antimicrobial peptides and the enteric mucus layer act in concert to protect the intestinal mucosa.Peptide 19-2.5 inhibits heparan sulfate-triggered inflammation in murine cardiomyocytes stimulated with human sepsis serumThe Synthetic Antimicrobial Peptide 19-2.5 Interacts with Heparanase and Heparan Sulfate in Murine and Human SepsisLipoproteins/peptides are sepsis-inducing toxins from bacteria that can be neutralized by synthetic anti-endotoxin peptides.Antimicrobial Peptide CMA3 Derived from the CA-MA Hybrid Peptide: Antibacterial and Anti-inflammatory Activities with Low Cytotoxicity and Mechanism of Action in Escherichia coliMicheliolide inhibits LPS-induced inflammatory response and protects mice from LPS challenge.Biophysical mechanisms of the neutralization of endotoxins by lipopolyamines.The synthetic antimicrobial peptide 19-2.5 attenuates septic cardiomyopathy and prevents down-regulation of SERCA2 in polymicrobial sepsisA review on comparative mechanistic studies of antimicrobial peptides against archaea.The synthetic antimicrobial peptide 19-2.5 attenuates mitochondrial dysfunction in cardiomyocytes stimulated with human sepsis serum.Synthetic antimicrobial and LPS-neutralising peptides suppress inflammatory and immune responses in skin cells and promote keratinocyte migration.Coupling killing to neutralization: combined therapy with ceftriaxone/Pep19-2.5 counteracts sepsis in rabbits.Lack of new antiinfective agents: Passing into the pre-antibiotic age?Immunogenic properties of the human gut-associated archaeon Methanomassiliicoccus luminyensis and its susceptibility to antimicrobial peptides.Biophysical Analysis of Lipopolysaccharide Formulations for an Understanding of the Low Endotoxin Recovery (LER) Phenomenon.Mechanism of Hbγ-35-induced an increase in the activation of the human immune system by endotoxins.The Synthetic Antimicrobial Peptide 19-2.5 Interacts With Heparanase and Heparan Sulfate in Murine Sepsis In Vivo and in Human Sepsis Ex Vivo.Application of immobilized synthetic anti-lipopolysaccharide peptides for the isolation and detection of bacteria.Antimicrobial Peptides and Their Therapeutic Potential for Bacterial Skin Infections and Wounds.
P2860
Q26782811-96A94EE6-9F14-415E-9C38-945B581F4965Q28072373-E452B182-53F8-4936-8FB8-74E1023D8E65Q28546690-B02E1278-29CD-473F-805C-7A9A35632872Q33729006-7956E957-AC09-4E07-8ADE-619DBE6132B4Q35498107-EDDBCABB-0B77-4ECE-8C30-E3EFFBF41201Q35646306-5C46DABA-31C3-4B58-B5EB-0CE68D8E5A09Q35850606-708C09BA-09C9-47D5-9E17-29B0F62214BDQ36099284-86577175-675F-4DF3-AADB-52CBA88AC861Q36439097-0AED9EE9-B101-41BB-BBE1-DF9E6B624787Q36693987-8BA390F1-32A4-40B4-82AE-BB34753F1C7AQ37226609-0F40F8D8-7EC0-412D-A37A-E4B3D5BC909CQ37419083-3DAC4506-2C82-4048-9FFE-08A98619E49BQ38653377-CD94BB18-1FCC-4D21-84E0-79AE7A7AB3A5Q38746473-45BE51DE-BD35-491A-96A9-507AB61634E8Q39503515-841FAEBD-72C1-4011-BBBB-C75623625089Q40170272-EB835A89-A4FD-4F16-969B-F6564F56FF90Q41024475-FA1DB259-B9D9-4983-A8E2-577C534DB957Q42370752-8C1EB2FC-F8C1-45F4-8FC1-B06A43BF784CQ47274883-A4BF7CB2-65D8-4E97-BC1D-14DF7300F247Q49996616-D50F78C7-0396-4320-8E19-C632D3EA8A29Q50417025-AF666F4E-E126-474A-BFAC-C7934A788492Q50975559-55858CF1-924A-480D-AE6E-91988AD5DD93Q52592947-D409ED3E-421E-486C-ACCA-8B820F9F57FD
P2860
Preclinical investigations reveal the broad-spectrum neutralizing activity of peptide Pep19-2.5 on bacterial pathogenicity factors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Preclinical investigations rev ...... cterial pathogenicity factors.
@ast
Preclinical investigations rev ...... cterial pathogenicity factors.
@en
type
label
Preclinical investigations rev ...... cterial pathogenicity factors.
@ast
Preclinical investigations rev ...... cterial pathogenicity factors.
@en
prefLabel
Preclinical investigations rev ...... cterial pathogenicity factors.
@ast
Preclinical investigations rev ...... cterial pathogenicity factors.
@en
P2093
P2860
P50
P356
P1476
Preclinical investigations rev ...... cterial pathogenicity factors.
@en
P2093
Aline Dupont
Guillermo Martinez de Tejada
Julius Brandenburg
Lena Heinbockel
Martin Ernst
Mathias Hornef
Sabine Dömming
Sebastian Marwitz
Thomas Gutsmann
Tobias Schürholz
P2860
P304
P356
10.1128/AAC.02066-12
P407
P577
2013-01-14T00:00:00Z